| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/17/2013 | US20130018059 Dimethyl sulfoxide (dmso) formulations for treating autism |
| 01/17/2013 | US20130018057 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/17/2013 | US20130018056 Method of treatment for mental disorders |
| 01/17/2013 | US20130018052 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 01/17/2013 | US20130018048 Oxazole derivatives useful as modulators of faah |
| 01/17/2013 | US20130018047 N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 01/17/2013 | US20130018043 Aminomethyl quinolone compounds |
| 01/17/2013 | US20130018038 Chemical compounds |
| 01/17/2013 | US20130018034 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| 01/17/2013 | US20130018031 Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
| 01/17/2013 | US20130018029 High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds |
| 01/17/2013 | US20130018024 Methods and systems for pharmacogenomic treatment of cardiovascular conditions |
| 01/17/2013 | US20130018019 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
| 01/17/2013 | US20130018017 Quinolinone derivatives as parp and tank inhibitors |
| 01/17/2013 | US20130018014 New class of therapeutics that enhance small molecule diffusion |
| 01/17/2013 | US20130018012 Lipid composition for improving brain function |
| 01/17/2013 | US20130017999 Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases |
| 01/17/2013 | US20130017998 Novel modified galectin 9 proteins and use thereof |
| 01/17/2013 | US20130017616 Methods For Treating Inflammation |
| 01/17/2013 | US20130017278 Composition and method for improving brain function |
| 01/17/2013 | US20130017276 Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication |
| 01/17/2013 | US20130017274 Low dose lithium in the treatment or prophylaxis of parkinson's disease |
| 01/17/2013 | US20130017269 Diane's manna |
| 01/17/2013 | US20130017262 Immediate/delayed drug delivery |
| 01/17/2013 | US20130017259 Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| 01/17/2013 | US20130017255 Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent |
| 01/17/2013 | US20130017254 Pharmaceutical formulation containing phenytoin sodium and magnesium stearate |
| 01/17/2013 | US20130017252 Method for Selectively Inhibiting the Activity of ACAT1 in the Treatment of Alzheimer's Disease |
| 01/17/2013 | US20130017251 Antibody Specific for Apolipoprotein and Methods of Use Thereof |
| 01/17/2013 | US20130017226 TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune Diseases |
| 01/17/2013 | US20130017209 A-beta binding polypeptides |
| 01/17/2013 | US20130017208 Anti-IL-6 Antibodies, Compositions, Methods and Uses |
| 01/17/2013 | US20130017206 Mcam modulation and uses thereof |
| 01/17/2013 | US20130017202 Pharmaceutical compositions and methods of treatment |
| 01/17/2013 | US20130017193 Antibody formulations |
| 01/17/2013 | US20130017190 Treatment of inflammatory diseases |
| 01/17/2013 | US20130017189 Functionalised Triblock Copolymers and Compositions Containing Such Polymers |
| 01/17/2013 | US20130017188 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| 01/17/2013 | US20130017183 Compositions containing non-polar compounds |
| 01/17/2013 | US20130017179 Lineage-Restricted Neuronal Precursors |
| 01/17/2013 | US20130017172 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus |
| 01/17/2013 | US20130017170 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/17/2013 | US20130017166 Protein-Poly(2-oxazoline) Conjugates for Enhanced Cellular Delivery and Transport Across Biological Barriers |
| 01/17/2013 | US20130017152 Method for the treatment of multiple sclerosis |
| 01/17/2013 | US20130017149 Pharmaceutical compounds |
| 01/17/2013 | DE19941675B4 2-Amino-bicyclo[3.1.0] hexan-2,6-dicarbonsäurederivate und ein Verfahren zu deren Herstellung 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives and a process for their preparation |
| 01/17/2013 | CA2878701A1 Neuroprotective pepties that inhbit interaction between palmitoyl acyl transferase zinc- finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk) |
| 01/17/2013 | CA2878259A1 Terpene analogues and uses thereof for treating neurological conditions |
| 01/17/2013 | CA2849213A1 Combination als therapy |
| 01/17/2013 | CA2841983A1 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/17/2013 | CA2841972A1 Terpene analogues and uses thereof for treating neurological conditions |
| 01/17/2013 | CA2841807A1 A new therapeutical composition containing apomorphine as active ingredient |
| 01/17/2013 | CA2841731A1 Nicotinamide compositions and the therapeutic use thereof |
| 01/17/2013 | CA2841534A1 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 01/17/2013 | CA2841169A1 Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse |
| 01/17/2013 | CA2841113A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 01/17/2013 | CA2840217A1 (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists |
| 01/17/2013 | CA2839844A1 Pharmaceutical composition for neurological disorders |
| 01/17/2013 | CA2839395A1 Aminomethyl quinolone compounds |
| 01/17/2013 | CA2837529A1 Positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/16/2013 | EP2546252A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546251A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546250A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546239A1 6-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2546238A1 6-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2546237A1 7-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2545939A2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| 01/16/2013 | EP2545919A1 Treatment of synucleinopathies |
| 01/16/2013 | EP2545915A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545914A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545055A1 Imidazo [1, 2 -a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
| 01/16/2013 | EP2545054A1 Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| 01/16/2013 | EP2545053A1 Azaisoquinolinone derivatives as nk3 antagonists |
| 01/16/2013 | EP2545047A1 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| 01/16/2013 | EP2545046A1 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| 01/16/2013 | EP2545037A1 Inhibitors of protein kinases |
| 01/16/2013 | EP2545033A2 Propionic acids, propionic acid esters, and related compounds |
| 01/16/2013 | EP2545027A1 Crystalline salts and/or cocrystals of o-desmethyltramadol |
| 01/16/2013 | EP2545025A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | EP2544700A1 Herbal composition for preventing and\or treating anxiety and related conditions |
| 01/16/2013 | EP2544694A2 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/16/2013 | EP2544690A2 Arylvinylazacycloalkane compounds for constipation |
| 01/16/2013 | EP2544688A2 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/16/2013 | EP2544542A1 Analgesic compounds, compositions, and uses thereof |
| 01/16/2013 | EP2544536A1 Fatty acid conjugates of quetiapine, process for making and using the same |
| 01/16/2013 | CN1812800B Muscle derived cells(mdc) for promoting and enhancing nerve repair and regeneration |
| 01/16/2013 | CN102884065A Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| 01/16/2013 | CN102884059A N-酰基环胺衍生物或其可药用盐 N- acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| 01/16/2013 | CN102884052A Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 01/16/2013 | CN102884048A Amino-heteroaryl derivatives as HCN blockers |
| 01/16/2013 | CN102884047A 2-pyridone compounds |
| 01/16/2013 | CN102884037A Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | CN102883739A Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
| 01/16/2013 | CN102883733A AGE production inhibitor |
| 01/16/2013 | CN102883719A Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration |
| 01/16/2013 | CN102883716A Dried plant tissue and plant tissue extract for ameliorating central nervous system degenerative diseases accompanied by learning/memory disorders, movement disorders and the like, and pharmaceutical agent and food or beverage each comprising the dri |
| 01/16/2013 | CN102876683A Conotoxin and biological preparation method and application thereof |
| 01/16/2013 | CN102876553A Preparation method of high-quality mung bean liquor |
| 01/16/2013 | CN102875653A Alpha-conotoxin peptide, and medical composition, preparation method and purpose thereof |
| 01/16/2013 | CN102875642A Compounds for enzyme inhibition |